Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
anonusers Placed a 'Sell' Sentiment on UNVC1 day ago
anonusers Placed a 'Buy' Sentiment on HOME3 days ago
anonusers Placed a 'Sell' Sentiment on WBA3 days ago
russurban Placed a 'Buy' Sentiment on VXRT3 days ago
russurban Placed a 'Buy' Sentiment on OTLK3 days ago
russurban Followed OTLK3 days ago
stockarticles Placed a 'Buy' Sentiment on BB3 days ago
stockarticles Followed BB3 days ago
stockarticles Placed a 'Buy' Sentiment on SNAPMore than a week ago
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  VXRT  •  OTLK  •  PINS  •  BB  •  TWTR  •  CGC  •  ARCI  •  LULU  •  SNAP  •  IRBT

January 1, 2016 Stock Pick: Adaptimmune Therapeutics plc (ADAP)

Stock Price: $12.06

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company, focused on the provision of cancer immunotherapy products based on its T-cell receptor platform.

ADAP went public in May of 2015 at $17.25 a share and reached a high of $21.57. It has a 52-week low of $7.07 reached in October of 2015.

Last year, ADAP secured $104 million in Series A funding and raised $191 million in the aforementioned IPO. As of June 30th, 2015, ADAP had $284.39 million in cash, cash equivalents and short-term investments. The company has total liabilities of only $41.0 million.

ADAP is trading at a market cap of only $853.67 million, making it look fairly undervalued considering that the company has their lead product candidate in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer.

ADAP recently crossed over its 50-day moving average at $9.81 and is starting to build the makings of an attractive chart since October 18th.

Speculative Score: 3

1 Being the Least Speculative and Most Confident

10 Being the Most Speculative and Possibly the Most Risky

Untitled Document